Lastly, the comparison between GBs with different levels of H3.3 expression did not reveal any potential association with relevant clinical markers, except for RNF213 (Figure 3A), for which mutations are linked to cerebrovascular pathologies [35] and are unfavorable in other cancers [36,37]. This evidence concerns the gene RNF213 and cancer.